GH safety workshop position paper

A critical appraisal of recombinant human GH therapy in children and adults

D. B. Allen, P. Backeljauw, M. Bidlingmaier, B. M K Biller, M. Boguszewski, P. Burman, G. Butler, K. Chihara, J. Christiansen, S. Cianfarani, P. Clayton, D. Clemmons, P. Cohen, F. Darendeliler, C. Deal, D. Dunger, E. M. Erfurth, J. S. Fuqua, A. Grimberg, M. Haymond & 20 others C. Higham, K. Ho, A. R. Hoffman, A. Hokken-Koelega, G. Johannsson, A. Juul, J. Kopchick, P. Lee, M. Pollak, S. Radovick, L. Robison, R. Rosenfeld, R. J. Ross, L. Savendahl, P. Saenger, H. Toft Sorensen, K. Stochholm, C. Strasburger, A. Swerdlow, M. Thorner

Research output: Contribution to journalArticle

Abstract

Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-Term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-Term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

Original languageEnglish (US)
Pages (from-to)P1-P9
JournalEuropean Journal of Endocrinology
Volume174
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Safety
Education
Pediatrics
Therapeutics
Endocrinology
Research
Publications
Neoplasms
Homeostasis
Pharmacology
Glucose
Mortality

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Allen, D. B., Backeljauw, P., Bidlingmaier, M., Biller, B. M. K., Boguszewski, M., Burman, P., ... Thorner, M. (2016). GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults. European Journal of Endocrinology, 174(2), P1-P9. https://doi.org/10.1530/EJE-15-0873

GH safety workshop position paper : A critical appraisal of recombinant human GH therapy in children and adults. / Allen, D. B.; Backeljauw, P.; Bidlingmaier, M.; Biller, B. M K; Boguszewski, M.; Burman, P.; Butler, G.; Chihara, K.; Christiansen, J.; Cianfarani, S.; Clayton, P.; Clemmons, D.; Cohen, P.; Darendeliler, F.; Deal, C.; Dunger, D.; Erfurth, E. M.; Fuqua, J. S.; Grimberg, A.; Haymond, M.; Higham, C.; Ho, K.; Hoffman, A. R.; Hokken-Koelega, A.; Johannsson, G.; Juul, A.; Kopchick, J.; Lee, P.; Pollak, M.; Radovick, S.; Robison, L.; Rosenfeld, R.; Ross, R. J.; Savendahl, L.; Saenger, P.; Toft Sorensen, H.; Stochholm, K.; Strasburger, C.; Swerdlow, A.; Thorner, M.

In: European Journal of Endocrinology, Vol. 174, No. 2, 01.02.2016, p. P1-P9.

Research output: Contribution to journalArticle

Allen, DB, Backeljauw, P, Bidlingmaier, M, Biller, BMK, Boguszewski, M, Burman, P, Butler, G, Chihara, K, Christiansen, J, Cianfarani, S, Clayton, P, Clemmons, D, Cohen, P, Darendeliler, F, Deal, C, Dunger, D, Erfurth, EM, Fuqua, JS, Grimberg, A, Haymond, M, Higham, C, Ho, K, Hoffman, AR, Hokken-Koelega, A, Johannsson, G, Juul, A, Kopchick, J, Lee, P, Pollak, M, Radovick, S, Robison, L, Rosenfeld, R, Ross, RJ, Savendahl, L, Saenger, P, Toft Sorensen, H, Stochholm, K, Strasburger, C, Swerdlow, A & Thorner, M 2016, 'GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults', European Journal of Endocrinology, vol. 174, no. 2, pp. P1-P9. https://doi.org/10.1530/EJE-15-0873
Allen, D. B. ; Backeljauw, P. ; Bidlingmaier, M. ; Biller, B. M K ; Boguszewski, M. ; Burman, P. ; Butler, G. ; Chihara, K. ; Christiansen, J. ; Cianfarani, S. ; Clayton, P. ; Clemmons, D. ; Cohen, P. ; Darendeliler, F. ; Deal, C. ; Dunger, D. ; Erfurth, E. M. ; Fuqua, J. S. ; Grimberg, A. ; Haymond, M. ; Higham, C. ; Ho, K. ; Hoffman, A. R. ; Hokken-Koelega, A. ; Johannsson, G. ; Juul, A. ; Kopchick, J. ; Lee, P. ; Pollak, M. ; Radovick, S. ; Robison, L. ; Rosenfeld, R. ; Ross, R. J. ; Savendahl, L. ; Saenger, P. ; Toft Sorensen, H. ; Stochholm, K. ; Strasburger, C. ; Swerdlow, A. ; Thorner, M. / GH safety workshop position paper : A critical appraisal of recombinant human GH therapy in children and adults. In: European Journal of Endocrinology. 2016 ; Vol. 174, No. 2. pp. P1-P9.
@article{bfa1d81d696b4ca484e70b8c6d6e1060,
title = "GH safety workshop position paper: A critical appraisal of recombinant human GH therapy in children and adults",
abstract = "Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-Term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-Term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.",
author = "Allen, {D. B.} and P. Backeljauw and M. Bidlingmaier and Biller, {B. M K} and M. Boguszewski and P. Burman and G. Butler and K. Chihara and J. Christiansen and S. Cianfarani and P. Clayton and D. Clemmons and P. Cohen and F. Darendeliler and C. Deal and D. Dunger and Erfurth, {E. M.} and Fuqua, {J. S.} and A. Grimberg and M. Haymond and C. Higham and K. Ho and Hoffman, {A. R.} and A. Hokken-Koelega and G. Johannsson and A. Juul and J. Kopchick and P. Lee and M. Pollak and S. Radovick and L. Robison and R. Rosenfeld and Ross, {R. J.} and L. Savendahl and P. Saenger and {Toft Sorensen}, H. and K. Stochholm and C. Strasburger and A. Swerdlow and M. Thorner",
year = "2016",
month = "2",
day = "1",
doi = "10.1530/EJE-15-0873",
language = "English (US)",
volume = "174",
pages = "P1--P9",
journal = "European Journal of Endocrinology",
issn = "0804-4643",
publisher = "BioScientifica Ltd.",
number = "2",

}

TY - JOUR

T1 - GH safety workshop position paper

T2 - A critical appraisal of recombinant human GH therapy in children and adults

AU - Allen, D. B.

AU - Backeljauw, P.

AU - Bidlingmaier, M.

AU - Biller, B. M K

AU - Boguszewski, M.

AU - Burman, P.

AU - Butler, G.

AU - Chihara, K.

AU - Christiansen, J.

AU - Cianfarani, S.

AU - Clayton, P.

AU - Clemmons, D.

AU - Cohen, P.

AU - Darendeliler, F.

AU - Deal, C.

AU - Dunger, D.

AU - Erfurth, E. M.

AU - Fuqua, J. S.

AU - Grimberg, A.

AU - Haymond, M.

AU - Higham, C.

AU - Ho, K.

AU - Hoffman, A. R.

AU - Hokken-Koelega, A.

AU - Johannsson, G.

AU - Juul, A.

AU - Kopchick, J.

AU - Lee, P.

AU - Pollak, M.

AU - Radovick, S.

AU - Robison, L.

AU - Rosenfeld, R.

AU - Ross, R. J.

AU - Savendahl, L.

AU - Saenger, P.

AU - Toft Sorensen, H.

AU - Stochholm, K.

AU - Strasburger, C.

AU - Swerdlow, A.

AU - Thorner, M.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-Term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-Term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

AB - Recombinant human GH (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-Term safety, including cancer risk, impact on glucose homeostasis, and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk, and the need for long-Term surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS, and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.

UR - http://www.scopus.com/inward/record.url?scp=84956654819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956654819&partnerID=8YFLogxK

U2 - 10.1530/EJE-15-0873

DO - 10.1530/EJE-15-0873

M3 - Article

VL - 174

SP - P1-P9

JO - European Journal of Endocrinology

JF - European Journal of Endocrinology

SN - 0804-4643

IS - 2

ER -